What About Add-On Second-Line Controller Therapy?
To the Editor:
The review by Roland et al (July 2004) 1 in CHEST has provided a timely reminder of the local adverse consequences of the use of inhaled corticosteroids in treating asthma. However, while playing an integral role in the management of inflammatory airways disease, inhaled corticosteroids are effective when used in smaller doses in combination with additional second-line controller therapy. 2 This is especially pertinent, and indeed is advised, in patients with mild-to-moderate disease whose conditions are suboptimally controlled with low-dose inhaled corticosteroids. 3 In their article, the authors do not mention the use of concomitant nonsteroidal antiinflammatory therapy with leukotriene receptor antagonists or long-acting ␤ 2 -agonists. Using these agents would obviously permit a lower inhaled corticosteroid dose to be used, while maintaining or even improving asthma control. 3 In turn, this would reduce the dose of corticosteroid delivered to both the oropharynx and endobronchial tree, minimizing the risk of both troublesome local and serious systemic sequelae. Common sense tells us that we should continue to advise patients to use a spacer device, rinse their mouths, and gargle after using an inhaled corticosteroid. Moreover, clinicians should be aware that the addition of second-line controller therapy with a concomitant reduction of inhaled corticosteroid dose should be considered when dealing with a patient with oropharyngeal candidiasis and dysphonia. Indeed, encountering an asthmatic patient with such problems provides an ideal opportunity to consider adjusting the burden of inhaled antiinflammatory therapy. 
To the Editor:
We read the letter from Dr. Currie with interest, and we agree with the issues raised in the letter.
Our article was primarily written to bring to everyone's attention the side effects of corticosteroids in the upper airway. We think that these quite distressing symptoms are often ignored.
The basic thrust of the article was to describe the side effects and to discuss what can be done for those patients who need therapy with inhaled steroids to control their symptoms. The assumption was that there are a large number of patients who are receiving full asthma treatment according to the guidelines, including long-acting ␤ 2 -antagonists and leukotreine antagonists, who still require large doses of inhaled steroids.
We fully accept that all patients would be treated according to the various guidelines, which clearly state that long-acting ␤-blockers are an integral part of asthma management when the dose of inhaled steroids is getting above 800 g/d (British Thorac Society guidelines). The latest British Thorac Society guidelines also have introduced add-on therapy at an earlier stage on the basic assumption that this provides better control and will have some steroid-sparing effect. In addition, there is now increasing evidence that doubling the dose of inhaled corticosteroids during an exacerbation is probably not very effective.
Leukotreine antagonists do seem to have some steroid-sparing effect for inhaled steroids (the effect for oral steroids is much more controversial). However, there is still considerable debate about the stage at which they should be used.
Thus, we agree with Dr. Currie that everything possible should be done to provide good asthma control, including the case of add-on therapies. However, even when all this is done, many 
Diagnosing Tubercular Pleural Effusions
We read with interest the article by Hikari et al (March 2004) 1 comparing the markers of tuberculosis in pleural effusions. We wish to express our disagreement with their statement that interferon (IFN)-␥ should be measured routinely in all suspected cases of pleural tuberculosis. They have based their conclusion on the basis of a perfect area under the curve of 1.000 on receiver operator characteristic analysis for IFN-␥ as compared to 0.958 for adenosine deaminase (ADA). The authors have failed to adequately review the fairly large body of literature on biological markers of tubercular pleural effusion.
ADA has been reported with perfect values in the literature (100% sensitivity, 2-4 and also 100% specificity, positive predictive value, and negative predictive value 5 ) in studies with larger sample sizes (n ϭ 221, 48 tuberculous 2 ; n ϭ 405, 91 tuberculous 3 ; n ϭ 350, 76 tuberculous 4 ; and n ϭ 138, and 61 tuberculous 5 ) than the present study (n ϭ 55, 20 tuberculous). 1 Valdes et al, 3 using simultaneous measurement in the same set of patients (n ϭ 405), reported a higher sensitivity for ADA (100%) than IFN-␥ (94.2%) and a higher specificity (95% for ADA and 91.8% for IFN-␥). Villegas et al 6 compared ADA and IFN-␥ (along with polymerase chain reaction [PCR]) simultaneously in 140 patients with 42 confirmed TB cases and reported a higher sensitivity (88.1% for ADA vs 85.7% for IFN-␥) and better negative predictive value than IFN in the whole prevalence range. Valdes et al 7 reported that 253 of a total of 254 tuberculous pleuritis patients had ADA levels Ͼ 40 IU/mL, and in the 82 patients in whom both ADA and IFN-␥ were done, the sensitivity of IFN was 89% (73 of 82 patients) against at least 98.78% (81 of 82 patients) for ADA.
Studies comparing ADA and IFN-␥ simultaneously in the same set of patients have reported both ADA better than IFN-␥ 2-7 and IFN-␥ better than ADA 1,8 -9 as diagnostic markers. In fact, a meta-analysis by Greco et al 10 regarding the diagnostic accuracy of ADA vs IFN-␥ included 31 studies in favor of ADA (total, n ϭ 4,738) and 13 studies in favor of IFN-␥ (total, n ϭ 1,189). Using summary receiver operating characteristic curve, they found only a marginal difference in overall sensitivity and specificity: 93% for ADA, and 96% for IFN-␥. Using Bayes theorem, the posttest probability of a negative test result was calculated. The minute difference in posttest probabilities (ADA vs IFN-␥, 0.4% vs 0.22%, 2.4% vs 1.2%, and 24% vs 17%) was maintained over a wide prevalence range of 5 to 85%. The authors concluded that "ADA and IFN-␥ appear to be reasonably accurate at detecting TB pleurisy." Virtually similar sensitivity and specificity coupled with lower cost should favor the use of ADA as a diagnostic tool compared to IFN-␥.
Lastly, the authors suggest that PCR should be compared with IFN, etc. Such a study comparing PCR, IFN, and ADA simultaneously in pleural effusion patients has already been published in CHEST. 6 Uday A. 
